IP10C8
- Generic Name
- IP10C8
Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2009-01-19
- Lead Sponsor
- Immune Technologies & Medicine GmbH
- Target Recruit Count
- 24
- Registration Number
- NCT00824980
- Locations
- 🇨ðŸ‡
University Hospital Zurich, Zurich, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath